Scimago Lab
powered by Scopus
Formerly the IP & Science
business of Thomson Reuters


eISSN: 1643-3750

Get your full text copy in PDF

Does alpha-1-proteinase inhibitor play a protective role in coronary atherosclerosis?

Donatas Stakisaitis, Vytautas Basys, Rimantas Benetis

Med Sci Monit 2001; 7(4): CR701-711

ID: 421082

BACKGROUND: alpha-1-proteinase inhibitor (alpha-1-PI) might appear to be actively involved in atherogenesis as an important regulator protecting elastic tissue from damage by proteinases as well as lipid accumulation in arterial wall.
MATERIALS AND METHODS: alpha-1-PI genetic variants were examined in 156 male coronary atherosclerosis patients (mean age 49+/-9 years). The frequency of alpha-1-PI phenotypes was determined in 1577 healthy individuals. Also, 108 long-survivors (mean age 92.7+/-4.3 years) were investigated for alpha-1-PI phenotype. The serum level of alpha-1-PI was examined in 43 coronary atherosclerosis patients (mean of age 49.6+/-8.1 years) and in different age groups of healthy males. A correlations between seruma-1-PI concentration and apoB, and apoA-1 were calculated. Relationship between serum alpha-1-PI and apolipoprotein B/apolipoprotein A-1 (apoB/apoA-1) ratio was determined. Isoelectric focusing of alpha-1-PI phenotypes was performed on thick polyacrylamide gels with ampholytes pH 3.5-5.0, 4.5-6.5 and 4.2-5.0. A quantitative assessment of alpha-1-PI, apoB and apoA-1 was performed by ELISA method using antibodies against human alpha-1-PI, apoB and apoA-1.
RESULTS: The phenotype PI ZZ of alpha-1-PI associated with a severe congenital deficiency of alpha-1-PI in patients and long-lived subjects was not found. In population this phenotype (0.06%) as well as PI SS phenotype (0.06%) was detected once. No significant difference was found in the frequency of PI*M, PI*S and PI*Z genes in the coronary atherosclerosis group and population. The PI*Z gene was significantly more frequent in patients with coronary atherosclerosis than in long-survivors (P<0.01). The correlation between blood serum (-1-PI concentration and age in the control group of males was significant (r=Ð0.83, P<0.01). The a-1-PI concentration was found significantly higher in coronary atherosclerosis patients compared with control (2.14±0.6 and 1.68±0.3 g/l respectively, P<0.05). The a-1-PI concentration was found to dependent on the apoB/apoA-1 ratio: it was higher in patients having apoB/apoA-1>1.0 than in patients with apoB/apoA-1<1.0 (2.4±0.6 and 2.04±0.5 g/l respectively, P<0.05). There was a significant correlation between a-1-PI concentration and apoB/apoA-1 ratio in blood serum of patients suffering from coronary atherosclerosis (r=0.25, P<0.05).
CONCLUSIONS: Derangements in the homeostasis of proteinase-antiproteinase system could be involved in destruction of the arterial wall connective tissue. The local as well as systemic inactivation of a-1-PI in atherosclerosis process could be related with hyperlipidemia. Investigation of long-survivors support the suggestion that they are important antiatherogenic control group for evaluating the role of genetic determinants in atherogenesis. Congenital (a-1-PI deficiency, hyperlipidemia) and acquired (related to smoking, aging) imbalance of proteinase-antiproteinase system is considered to one of the atherogenic factors. Authors discuss the possible mechanisms of atherogenesis related with imbalance of proteinase-antiproteinase system.

This paper has been published under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) allowing to download articles and share them with others as long as they credit the authors and the publisher, but without permission to change them in any way or use them commercially.
I agree